AVITA Medical's RECELL System Demonstrates 36% Reduction in Hospital Stay for Burn Patients
核心洞察
Real-world data from the U.S. national burn registry shows RECELL System reduces hospital length of stay by 36% compared to traditional skin grafting in adults with deep second-degree burns.
The treatment achieves potential cost savings exceeding $42,000 per patient and enables hospitals to treat 13 more patients per bed annually.
AVITA Medical's FDA-approved RECELL GO mini system launched in 2024 addresses smaller wounds and expands the addressable market from $455 million to over $3.5 billion in the U.S.
Real-world data from the U.S. national burn registry demonstrates that AVITA Medical's RECELL® System significantly reduces hospital length of stay by an average of 36% compared to traditional split thickness skin grafts in adult patients with deep partial thickness burns affecting up to 30% total body surface area. The findings were presented at the 2025 European Burn Association Congress in Berlin, Germany.
Clinical Outcomes and Economic Impact
In a matched analysis of 741 adults from the Burn Care Quality Platform registry, patients treated with RECELL (n=247) experienced an average 5.6-day reduction in hospital length of stay compared to those treated with traditional skin grafts (n=494; p < 0.0001). A greater proportion of RECELL-treated patients were discharged directly home, indicating improved recovery trajectories.
Victoria Miles, EMTP, MD, of Louisiana State University Health and Sciences Center, who presented the research, stated: "These findings support the role of RECELL as a clinically validated, cost-effective option in modern burn management, and highlight the impact on patient outcomes, hospital efficiency, and resource utilization."
The economic implications are substantial. Based on an estimated average daily inpatient bed cost of $7,554, the use of RECELL is associated with potential per patient cost savings exceeding $42,000, exclusive of procedure and rehabilitation costs. The reduction in hospital stay may enable hospitals to treat 13 more patients per bed annually compared to treatment with traditional skin grafts alone.
Technology and Mechanism
RECELL harnesses the regenerative properties of a patient's own skin to create an autologous skin cell suspension autograft, enabling clinicians to deliver treatment at the point of care. The system creates Spray-On Skin™ Cells that accelerate wound healing while requiring 97.5% less skin compared to split-thickness skin grafts, with significantly improved donor site healing, pain, and scarring outcomes.
Market Context and Healthcare Burden
The study's findings address a growing need to reduce the burden of burn care on hospital systems. In 2023 alone, U.S. burn cases consumed more than 110,000 ICU days, costing in excess of $676 million, according to the 2024 ABA Annual Burn Injury Summary Report.
Product Portfolio Expansion
AVITA Medical received FDA clearance in 2024 for the RECELL GO mini, designed to treat smaller full-thickness wounds up to 480 cm². This addresses a critical gap in the market where trauma and burn centers frequently encounter smaller wounds that are inefficient to treat with the standard 1,920 cm² system. The mini system's rollout began in Q1 2025, initially targeting trauma centers.
The company has also launched Cohealyx (搜索)™, a collagen-based dermal matrix, expanding its addressable market from $455 million to over $3.5 billion in the U.S. Additionally, AVITA holds exclusive rights to manufacture and distribute PermeaDerm (搜索)®, a biosynthetic wound matrix.
Regulatory and Reimbursement Progress
The Centers for Medicare and Medicaid Services approved a New Technology Add-on Payment for trauma wound treatments in 2025. However, AVITA faced temporary Medicare Administrative Contractor payment delays in early 2025, causing a 20% decline in demand and $10 million in lost revenue. Multiple MACs resumed adjudicating claims in July 2025, with full resolution expected by Q3 2025.
International Presence
Internationally, the RECELL System has received regulatory approvals in key markets, including TGA registration in Australia, CE mark approval in Europe, and PMDA approval in Japan, enabling global market expansion.
Financial Outlook
AVITA demonstrated disciplined cost management with operating expenses declining to $26.1 million in Q2 2025. The company renegotiated its credit agreement with OrbiMed (搜索), lowering revenue covenants and issuing common stock in lieu of cash for additional flexibility. Management anticipates achieving cash flow break-even by Q2 2026 and GAAP profitability by Q3 2026.
Jim Corbett, Chief Executive Officer of AVITA Medical, commented: "The results from this real-world analysis underscore the transformative potential of RECELL in reducing hospitalization time and improving care efficiency. These insights reaffirm our commitment to delivering clinically meaningful solutions that benefit patients, providers, and the broader healthcare system."